REDCARE PHARMACY NV (RDC.DE) Fundamental Analysis & Valuation

FRA:RDC • NL0012044747

Current stock price

33.24 EUR
-1.26 (-3.65%)
Last:

This RDC.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. RDC.DE Profitability Analysis

1.1 Basic Checks

  • In the past year RDC has reported negative net income.
  • RDC had a positive operating cash flow in the past year.
  • RDC had negative earnings in each of the past 5 years.
  • Of the past 5 years RDC 4 years had a positive operating cash flow.
RDC.DE Yearly Net Income VS EBIT VS OCF VS FCFRDC.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M

1.2 Ratios

  • RDC has a worse Return On Assets (-3.10%) than 81.48% of its industry peers.
  • Looking at the Return On Equity, with a value of -8.21%, RDC is doing worse than 81.48% of the companies in the same industry.
Industry RankSector Rank
ROA -3.1%
ROE -8.21%
ROIC N/A
ROA(3y)-2.94%
ROA(5y)-5.79%
ROE(3y)-6.64%
ROE(5y)-11.93%
ROIC(3y)N/A
ROIC(5y)N/A
RDC.DE Yearly ROA, ROE, ROICRDC.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5 -10 -15 -20

1.3 Margins

  • RDC has a Gross Margin of 22.57%. This is comparable to the rest of the industry: RDC outperforms 48.15% of its industry peers.
  • RDC's Gross Margin has been stable in the last couple of years.
  • RDC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 22.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.42%
GM growth 5Y-0.09%
RDC.DE Yearly Profit, Operating, Gross MarginsRDC.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. RDC.DE Health Analysis

2.1 Basic Checks

  • RDC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for RDC remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, RDC has more shares outstanding
  • Compared to 1 year ago, RDC has a worse debt to assets ratio.
RDC.DE Yearly Shares OutstandingRDC.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
RDC.DE Yearly Total Debt VS Total AssetsRDC.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 2.74 indicates that RDC is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • With a Altman-Z score value of 2.74, RDC perfoms like the industry average, outperforming 40.74% of the companies in the same industry.
  • A Debt/Equity ratio of 0.72 indicates that RDC is somewhat dependend on debt financing.
  • With a decent Debt to Equity ratio value of 0.72, RDC is doing good in the industry, outperforming 66.67% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.72
Debt/FCF N/A
Altman-Z 2.74
ROIC/WACCN/A
WACC5.9%
RDC.DE Yearly LT Debt VS Equity VS FCFRDC.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • RDC has a Current Ratio of 1.55. This is a normal value and indicates that RDC is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.55, RDC belongs to the top of the industry, outperforming 92.59% of the companies in the same industry.
  • A Quick Ratio of 1.01 indicates that RDC should not have too much problems paying its short term obligations.
  • With an excellent Quick ratio value of 1.01, RDC belongs to the best of the industry, outperforming 88.89% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.55
Quick Ratio 1.01
RDC.DE Yearly Current Assets VS Current LiabilitesRDC.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. RDC.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 17.77% over the past year.
  • The Revenue has grown by 24.06% in the past year. This is a very strong growth!
  • RDC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.89% yearly.
EPS 1Y (TTM)17.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.7%
Revenue 1Y (TTM)24.06%
Revenue growth 3Y34.66%
Revenue growth 5Y24.89%
Sales Q2Q%17.75%

3.2 Future

  • RDC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 75.50% yearly.
  • Based on estimates for the next years, RDC will show a quite strong growth in Revenue. The Revenue will grow by 14.66% on average per year.
EPS Next Y109.46%
EPS Next 2Y82.58%
EPS Next 3Y92.25%
EPS Next 5Y75.5%
Revenue Next Year18.46%
Revenue Next 2Y17.13%
Revenue Next 3Y17.51%
Revenue Next 5Y14.66%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
RDC.DE Yearly Revenue VS EstimatesRDC.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2B 4B 6B
RDC.DE Yearly EPS VS EstimatesRDC.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 5 10

More info and screens

Find the best growth stocksShow best growing peers

1

4. RDC.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RDC. In the last year negative earnings were reported.
  • Based on the Price/Forward Earnings ratio of 235.82, the valuation of RDC can be described as expensive.
  • Based on the Price/Forward Earnings ratio, RDC is valued more expensive than 85.19% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 23.28. RDC is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 235.82
RDC.DE Price Earnings VS Forward Price EarningsRDC.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150 200

4.2 Price Multiples

  • 70.37% of the companies in the same industry are cheaper than RDC, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 16.58
RDC.DE Per share dataRDC.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 100

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • A more expensive valuation may be justified as RDC's earnings are expected to grow with 92.25% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y82.58%
EPS Next 3Y92.25%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RDC.DE Dividend Analysis

5.1 Amount

  • RDC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RDC.DE Fundamentals: All Metrics, Ratios and Statistics

REDCARE PHARMACY NV

FRA:RDC (3/20/2026, 7:00:00 PM)

33.24

-1.26 (-3.65%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupConsumer Staples Distribution & Retail
GICS IndustryConsumer Staples Distribution & Retail
Earnings (Last)03-03
Earnings (Next)05-06
Inst Owners52.75%
Inst Owner ChangeN/A
Ins Owners7.32%
Ins Owner ChangeN/A
Market Cap684.08M
Revenue(TTM)2.94B
Net Income(TTM)-37.70M
Analysts80
Price Target131.3 (295.01%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-60.52%
Min EPS beat(2)-108.23%
Max EPS beat(2)-12.8%
EPS beat(4)2
Avg EPS beat(4)54.9%
Min EPS beat(4)-108.23%
Max EPS beat(4)313.82%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.72%
Min Revenue beat(2)-1.9%
Max Revenue beat(2)-1.55%
Revenue beat(4)0
Avg Revenue beat(4)-1.34%
Min Revenue beat(4)-1.9%
Max Revenue beat(4)-0.77%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.41%
PT rev (3m)-9.87%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-28.88%
EPS NY rev (3m)-66.71%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.81%
Revenue NY rev (3m)-1.81%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 235.82
P/S 0.23
P/FCF N/A
P/OCF 22.07
P/B 1.49
P/tB 10.41
EV/EBITDA 16.58
EPS(TTM)-1.49
EYN/A
EPS(NY)0.14
Fwd EY0.42%
FCF(TTM)-4.26
FCFYN/A
OCF(TTM)1.51
OCFY4.53%
SpS142.9
BVpS22.31
TBVpS3.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -3.1%
ROE -8.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 22.57%
FCFM N/A
ROA(3y)-2.94%
ROA(5y)-5.79%
ROE(3y)-6.64%
ROE(5y)-11.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.42%
GM growth 5Y-0.09%
F-Score4
Asset Turnover2.42
Health
Industry RankSector Rank
Debt/Equity 0.72
Debt/FCF N/A
Debt/EBITDA 6.97
Cap/Depr 170.89%
Cap/Sales 4.03%
Interest Coverage N/A
Cash Conversion 65.4%
Profit Quality N/A
Current Ratio 1.55
Quick Ratio 1.01
Altman-Z 2.74
F-Score4
WACC5.9%
ROIC/WACCN/A
Cap/Depr(3y)99.8%
Cap/Depr(5y)118.99%
Cap/Sales(3y)2.65%
Cap/Sales(5y)3.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.7%
EPS Next Y109.46%
EPS Next 2Y82.58%
EPS Next 3Y92.25%
EPS Next 5Y75.5%
Revenue 1Y (TTM)24.06%
Revenue growth 3Y34.66%
Revenue growth 5Y24.89%
Sales Q2Q%17.75%
Revenue Next Year18.46%
Revenue Next 2Y17.13%
Revenue Next 3Y17.51%
Revenue Next 5Y14.66%
EBIT growth 1Y42.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year865.74%
EBIT Next 3Y160.07%
EBIT Next 5Y114.99%
FCF growth 1Y-337.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.11%
OCF growth 3YN/A
OCF growth 5Y11.73%

REDCARE PHARMACY NV / RDC.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of REDCARE PHARMACY NV (RDC.DE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to RDC.DE.


Can you provide the valuation status for REDCARE PHARMACY NV?

ChartMill assigns a valuation rating of 1 / 10 to REDCARE PHARMACY NV (RDC.DE). This can be considered as Overvalued.


Can you provide the profitability details for REDCARE PHARMACY NV?

REDCARE PHARMACY NV (RDC.DE) has a profitability rating of 1 / 10.


What is the expected EPS growth for REDCARE PHARMACY NV (RDC.DE) stock?

The Earnings per Share (EPS) of REDCARE PHARMACY NV (RDC.DE) is expected to grow by 109.46% in the next year.